MONALEESA-3 was a randomized double-blind, placebo-managed study of ribociclib in combination with fulvestrant for that treatment method of postmenopausal Girls with hormone receptor constructive, HER2-destructive, advanced breast cancer which have gained no or only one line of prior endocrine treatment.Useful party coverage brokers, who will suppo